Vanderbilt Ingram Cancer Center

Phila Hach recently celebrated her 89th birthday and she has had much to celebrate over the years.

Health care professionals who care for cancer patients can experience strong emotions with limited opportunities to cope with or express those emotions. During September, Vanderbilt-Ingram Cancer Center and its partners are offering a series of free writing seminars for those health care professionals.

Carlos L. Arteaga, M.D., the Donna S. Hall Professor of Breast Cancer and director of the Center for Cancer Targeted Therapies and the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been recognized for his cancer research efforts by the American-Italian Cancer Foundation (AICF).

Cancer affects many families, and patients and their relatives often struggle with an effective way to describe their feelings about the illness and its aftermath.

Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.

Jeffrey Rathmell, Ph.D., has been recruited to Vanderbilt University Medical Center (VUMC) to lead a new Center for Immunobiology, a structure supported by the Department of Pathology, Microbiology and Immunology, the Department of Medicine and Vanderbilt-Ingram Cancer Center (VICC).

Vanderbilt-Ingram Cancer Center (VICC) investigators and colleagues at several major medical centers have been testing a new targeted therapy that is showing promise for the treatment of a rare tumor that forms in and around joint cavities.